Key Points
- Kevin J. Fitzgerald sold 2,290 Alnylam shares on Jan. 13 at an average price of $370.33 for a total of $848,055.70, cutting his ownership by 9.72% to 21,264 shares; he also sold additional blocks on Jan. 12 and Nov. 17.
- Multiple insiders (including the CEO and other EVPs) disclosed sizable stock sales on Jan. 12–13, which coincided with a market pullback and added negative sentiment toward ALNY.
- Despite the insider selling and short-term volatility, analysts remain largely bullish with a consensus rating of "Moderate Buy" and an average price target of about $490.96, while the company trades with a market cap near $48.5 billion.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,510 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president owned 23,554 shares of the company's stock, valued at $8,547,039.98. This represents a 6.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kevin Joseph Fitzgerald also recently made the following trade(s):
- On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70.
- On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04.
Alnylam Pharmaceuticals Stock Down 0.8%
Alnylam Pharmaceuticals stock opened at $366.86 on Thursday. The firm has a 50 day simple moving average of $422.03 and a 200 day simple moving average of $421.56. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The firm has a market capitalization of $48.47 billion, a price-to-earnings ratio of 1,528.58 and a beta of 0.32.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and set a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Leerink Partners reduced their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a "market perform" rating for the company in a research note on Monday, December 15th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, November 4th. Finally, Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a "buy" rating for the company in a report on Monday. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $490.96.
Read Our Latest Stock Analysis on ALNY
Alnylam Pharmaceuticals News Roundup
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $30,000. Finally, Ameriflex Group Inc. bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $32,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
